Adams Street Partners’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Adams Street Partners’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-490,707	Closed	-$2.01M	–	17
2017 Q4	$2.01M	Sell	490,707 -982,354	-67%	-$4.27M	0.48%	8
2017 Q3	$6.66M	Sell	1,473,061 -366,669	-20%	-$1.49M	1.7%	5
2017 Q2	$6.13M	Hold	1,839,730	–	–	1.44%	6
2017 Q1	$16.9M	Hold	1,839,730	–	–	4.17%	4
2016 Q4	$14.2M	Hold	1,839,730	–	–	3.9%	5
2016 Q3	$19.6M	Hold	1,839,730	–	–	3.7%	5
2016 Q2	$22.6M	Hold	1,839,730	–	–	3.71%	5
2016 Q1	$18.6M	Hold	1,839,730	–	–	3.39%	6
2015 Q4	$41.5M	Buy	1,839,730 +176,080	+11%	+$3.61M	7.46%	4
2015 Q3	$27.6M	Hold	1,663,650	–	–	5.86%	3
2015 Q2	$37.4M	Hold	1,663,650	–	–	5.63%	4
2015 Q1	$42.9M	Buy	+1,663,650	New	+$42.2M	6.84%	3

Other funds holding OMED

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Adams Street Partners's OMED Position: Q1 2018 in Review

Adams Street Partners sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2018, closing a stake of 490,707 shares — an estimated $2.01M sold.

Adams Street Partners first reported a position in OMED in Q1 2015 and held it in 12 quarters. The position peaked at $42.9M in Q1 2015. 66 funds tracked by Wall St. Rank hold OMED as of Q1 2018.

Adams Street Partners reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Adams Street Partners sold 490,707 OncoMed Pharmaceuticals, Inc. shares in Q1 2018, an estimated $2.01M.
Adams Street Partners first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2015 and held it in 12 quarters.
Adams Street Partners's OncoMed Pharmaceuticals, Inc. position peaked at $42.9M in Q1 2015.
66 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2018.

Based on Adams Street Partners's 13F filing for Q1 2018, filed 14 May 2018.